References
- Kurbacher C M, Mallmann P K. Chemoprotection in anticancer therapy: the emerging role of amifostine. Anticancer Res 1998; 18(3C)2203–2210
- Schuchter L M. Exploration of paltinum-based dose intensive chemotherapy strategies with amifostine. Eur J Cancer 1996; 32A(S4)S40–S42
- Budd G T, Ganapathi R, Bukowski R M, et al. Clinical effects of amifostine in patients treated with carboplatin. Eur J Cancer 1996; 32A(S4)43–45
- Capizzi R L. The preclinical aspects for broad spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 1999; 26(2)(S7)3–21
- Calabro-Jones P M, Fahey R C, Smoluk G D, et al. Alkaline phosphatase promotes radioprotection and acumulation of WR 1065 in V79–171 cells incubated in medium containing WR 2721. Int J Radiat Biol 1985; 47: 23–27
- Utley J F, Seaver N, Newton G L, et al. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR 2721. Int J Radiat Oncol Biol Phys 1984; 10: 1525–1528
- Yang J L, Fernandes D J, Speicher L, et al. Biochemical determinants of the cytoprotective effect of amifostine. Proc Am Assoc Cancer Res 1995; 36: 290
- Van Der Vjigh W JF, Peters G J. Protection of lnormal tissues from the cytotoxic effects of chemotherapy and radiation by amisfostine (ethyol): preclinical aspects. Semin Oncol 1994; 21(Suppl 11)2–7
- Capizzi R L. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (ethyol): clinical experiences. Semin Oncol 1994; 21(Suppl 11)8–15
- Glover D J, Glick J H, Weiter C, et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986; 4: 584–588
- Glover D J, Glick J H, Weiler C, et al. WR-2721 and high dose cisplatin: an active combination on the treatment of metastasic melanoma. J Clin Oncol 1987, 5: 574–578
- Chuang V P, Benjamin R, Jaffe N, et al. Radiographic and angiographic changes in osteosarcoma after intraarterial chemotherapy. AJR 1982; 139: 1065–1069
- Jaffe N. Pediatric osteosarcoma: treatment of the primary tumor with intraarterial cis-diamminedichloroplatinum-II (CDP): advantages, disadvantages, and controversial issues. Cancer Treat Res 1993; 62: 75–84
- Petrilli A S, Oliveira D T, Ginani V C, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol 2002; 24: 188–191
- Gilmer Knight K R, Kraemer D F, Neuwelt E A. Ototoxicity in children receiving platinum chemotherapy: underestimating a common occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23: 8588–8596
- Marina N, Chang K W, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Childrens Oncology Group study. Cancer 2005; 104: 841–847
- Glick J H, Kemp G, Rose P, et al. A randomized trial of cyclophosphamide and cisplatin ± amifostine in the treatment of advanced epithelial ovarian cancer. Proc Assoc Clin Oncol 1994; 13: 432